الفهرس 
Assessment of serum insulin- like growth factor binding proteins II and III as diagnostic and prognostic factors for Hepatitis C- related hepatocellular carcinoma
AbstractOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
insulin-like growth factor-binding protein-2 and-3 can serve as biomarkers in hepatocellular carcinoma (HCC).
Aim: The aim was to study the relation between IGFBP-2 and IGFBP-3 and the development, characteristics, and outcomes of chronic hepatitis-C (CHC) -related HCC.
Methods: This prospective study included patients with CHC with and without HCC who presented between 15 August 2018 and 16 March 2019, and followed till death or the end of the study. Baseline serum IGFBP-2 and IGFBP-3 were measured using enzyme-linked immunosorbent assays. We studied the patients’ tumour characteristics, treatment, and overall survival.
Results: The study included 82 patients with HCC and 81 non-HCC patients. Twenty-five (30.5%) patients developed HCC following therapy with direct-acting antivirals (DAAs). IGFBP-2 was significantly higher in patients with HCC compared with non-HCC [440.49 (93.60-729.17) ng/mL vs 184.00 (138.00-284.00) ng/mL, respectively, P <0.001.IGFBP-3 was significantly lower in patients with HCC [836.45 (733.00-1137.00) ng/mL vs 1702.70 (836.50-3141.40) ng/mL respectively, P <0.001). No difference was found in IGFBP-2 or IGFBP-3 levels with regard to previous DAAs therapy. The independent predictors of HCC development were age [odds ratio(OR)=1.291, 95% confidence interval (CI)=1.163-1.432, , P <0.001] ,liver stiffness measurement (OR=1.125, 95% CI =1.056-1.199, P <0.001), IGFBP-2 (OR=1.002, 95%CI =1.001-1.003, P =0.002), and IGFBP-3 (OR=0.998, 95%CI=0.997-0.999, P =0.001). The independent predictors of mortality were IGFBP-3 (OR =1.002, 95%CI =1.000-1.003), age (OR =0.876, 95%CI =0.808-0.950), and tumour size (OR =1.246, 95%CI =1.002-1.549).
Conclusion: Our results indicate a correlation between IGFBP-2 and IGFBP-3 levels and CHC-related HCC development and progression. IGFBP-2 and IGFBP-3 were not affected by previous DAAs therapy.
.